CAMR.F Stock Overview
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Camurus AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr46.15 |
| 52 Week High | kr51.65 |
| 52 Week Low | kr46.15 |
| Beta | 0.84 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 199.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| CAMR.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 0.08% | 1.2% |
| 1Y | n/a | 13.2% | 24.9% |
Return vs Industry: Insufficient data to determine how CAMR.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CAMR.F performed against the US Market.
Price Volatility
| CAMR.F volatility | |
|---|---|
| CAMR.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CAMR.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CAMR.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 213 | Fredrik Tiberg | www.camurus.com |
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon.
Camurus AB (publ) Fundamentals Summary
| CAMR.F fundamental statistics | |
|---|---|
| Market cap | US$2.56b |
| Earnings (TTM) | US$39.66m |
| Revenue (TTM) | US$157.81m |
64.5x
P/E Ratio16.2x
P/S RatioIs CAMR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CAMR.F income statement (TTM) | |
|---|---|
| Revenue | kr1.72b |
| Cost of Revenue | kr122.35m |
| Gross Profit | kr1.59b |
| Other Expenses | kr1.16b |
| Earnings | kr431.44m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | 7.49 |
| Gross Margin | 92.87% |
| Net Profit Margin | 25.13% |
| Debt/Equity Ratio | 0% |
How did CAMR.F perform over the long term?
See historical performance and comparison